Marker Therapeutics, Inc. (MRKR) Q2 2024 Earnings
MRKR·Reported August 14, 2024·Before market open
Marker Therapeutics, Inc. reported Q2 2024 revenue of $1.2M. Diluted EPS came in at $-0.29, beat the $-0.43 consensus by $0.14.
Revenue
$1.2M
Diluted EPS
$-0.29beat by $0.14
Consensus: $-0.43
Financial Snapshot
Trailing eight quarters through Q2 2024
Q2 2024 Earnings FAQ
Common questions about Marker Therapeutics, Inc.'s Q2 2024 earnings report.
Marker Therapeutics, Inc. (MRKR) reported Q2 2024 earnings on August 14, 2024 before market open.
Marker Therapeutics, Inc. reported revenue of $1.2M and diluted EPS of $-0.29 for Q2 2024.
EPS beat the consensus estimate of $-0.43 by $0.14.
You can read the 10-Q periodic report (0001410578-24-001454) directly on SEC EDGAR. The filing index links above go to sec.gov.